Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile

Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile
Published Oct 18, 2016
72 pages — Published Oct 18, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Cepheid is a molecular diagnostic company which develops, manufactures, and markets accurate and easy-to-use molecular systems and tests for clinical and non-clinical markets. The company offers invitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; systems that integrate sample preparation, DNA amplification and detection and analyze complex biological samples in our proprietary test cartridges; industrial reagents and parts and accessories for its systems.

Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical Equipment eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial m

  
Source:
Document ID
GDME7437D
Country
Industry
Ticker
CPHD=US
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Cepheid, Medical Equipment, Deals By Year, 2010 to YTD 201652
Cepheid, Medical Equipment Deals By Type, 2010 to YTD 201671
Cepheid, Medical Equipment, Deals By Region, 2010 to YTD 201681
Cepheid, Medical Equipment, Deals By Market, 2010 to YTD 201691
Cepheid, Medical Equipment, Deals Summary, 2010 to YTD 2016102
Cepheid, Medical Equipment, Deal Details1226
  Partnerships121
    Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics121
    Quidel Enters Into Licensing Agreement With Northwestern University And Northwestern Global Health Foundation131
    Novacyt Enters into Partnership with Cepheid141
    Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics151
    Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers162
    Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK181
    Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University191
    InGen BioSciences Enters Into Distribution Agreement With Quidel201
    InGen BioSciences Enters Into Distribution Agreement With Diagnostic Hybrids211
    Life Technologies Enters Into Co-Marketing Agreement With Quidel221
    Cepheid Enters Into Co-Development Agreement With FIND231
    Cepheid Enters Into Collaboration With Novartis241
    Cepheid Terminates Licensing Agreement With Roche251
  Equity Offering261
    Quidel Completes Underwritten Public Offering Of US$60 Million262
  Debt Offering281
    Quidel Prices Public Offering of 3.25% Senior Notes Due 2020282
    Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million302
  Acquisition321
    Danaher to Acquire Cepheid322
    Quidel Acquires AnDiaTec, Molecular Diagnostics Company341
    Quidel Acquires BioHelix, Molecular Diagnostic Company, For US$10 Million351
    Quidel Completes Acquisition Of Diagnostic HYBRIDS362
Cepheid - Key Competitors381
Key Employees391
Locations And Subsidiaries402
  Head Office401
  Other Locations &Subsidiaries402
Recent Developments421
Financial Announcements421
Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results421
Apr 28, 2016: Cepheid Reports First Quarter 2016 Results431
Feb 02, 2016: Cepheid Reports Fourth Quarter And Full Year 2015 Results441
Oct 20, 2015: Cepheid Reports 2015 Third Quarter Results451
Oct 13, 2015: Cepheid Reports Preliminary Results For 2015 Third Quarter461
Jul 23, 2015: Cepheid Reports 2015 Second Quarter Results471
Apr 23, 2015: Cepheid Reports 2015 First Quarter Results481
Jan 29, 2015: Cepheid Reports Fourth Quarter And Full Year 2014 Results491
Corporate Communications501
Feb 10, 2016: Cepheid Announces Appointment of President and Chief Operating Officer and Welcomes Executive Vice President of Engineering and Operations501
Apr 07, 2015: Cepheid Welcomes Executive Vice President And Chief Financial Officer511
Legal and Regulatory521
Jan 07, 2016: USAID And Cepheid Plan Collaboration To Accelerate Global Diagnosis Of Multidrug-Resistant Tuberculosis521
Product News531
Mar 09, 2016: Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant 'Superbugs'531
Dec 07, 2015: Cepheid Obtains FDA 510(k) Approval For Xpert Flu+RSV Xpress Test541
Jul 29, 2015: 'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms551
Jul 28, 2015: Cepheid Launches New Portable Molecular Diagnostics System At AACC561
May 13, 2015: WHO Lists Cepheid's Xpert Ebola as Eligible for Procurement to Ebola Affected Countries571
Apr 16, 2015: Cepheid And FIND's Xpert HIV-1 Qual Test Receives European Approval581
Apr 15, 2015: Cepheid Announces European Approval of Xpert HCV Viral Load591
Mar 24, 2015: Cepheid's Xpert Ebola Diagnostic Test Gets FDA Emergency Use Authorisation601
Mar 24, 2015: On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF Test Cartridge611
Feb 13, 2015: Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test621
Product Approvals631
Mar 09, 2016: Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant 'Superbugs'631
Dec 07, 2015: Cepheid Obtains FDA 510(k) Approval For Xpert Flu+RSV Xpress Test641
Apr 16, 2015: Cepheid And FIND's Xpert HIV-1 Qual Test Receives European Approval651
Apr 15, 2015: Cepheid Announces European Approval of Xpert HCV Viral Load661
Mar 24, 2015: Cepheid's Xpert Ebola Diagnostic Test Gets FDA Emergency Use Authorisation671
Feb 13, 2015: Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test681
Other Significant Developments691
Apr 21, 2016: Cepheid Announces Partner Distribution Agreement With Medline691
Dec 01, 2015: Cepheid Reaffirms 2015 Outlook At Piper Jaffray Healthcare Conference701
Jun 10, 2015: New Approach on HIV Viral Load Testing711
Appendix721
  Methodology721
  About GlobalData721
  Contact Us721
  Disclaimer721

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile" Oct 18, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Cepheid-CPHD-Medical-Equipment-Deals-and-Alliances-Profile-2148-6418>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Cepheid (CPHD) - Medical Equipment - Deals and Alliances Profile Oct 18, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Cepheid-CPHD-Medical-Equipment-Deals-and-Alliances-Profile-2148-6418>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research